SEHK:1672Biotechs
Ascletis Pharma (SEHK:1672) Following FDA Clearance Looks About Right At 3.8x P B
Ascletis Pharma (SEHK:1672) has kicked off a U.S. Phase I trial for its oral obesity candidate ASC36 after securing FDA Investigational New Drug clearance, bringing fresh attention to this Hong Kong biotech’s pipeline.
Investors have reacted cautiously in the short term, with the share price down 10.43% over the past month and 17.97% year to date. Ascletis Pharma still carries a very large 3 year total shareholder return and a 5 year total shareholder return above 200%, which suggests that...